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Lab Note
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Running title: Vitamin D enzymes and non-melanoma skin cancer

The relationship between vitamin D metabolic enzymes (CYP27A1, CYP27B1, and
CYP24A1) and vitamin D receptor (VDR) in non-melanoma skin cancer (NMSC)
development and progression is not entirely clear. However, several clinical studies and in
vitro reports indicate a connection between vitamin D metabolic key players and NMSCs
by demonstrating inhibitory effects on tumor cells and positive effects of higher circulatory
25-hydroxyvitamin D in skin cancer prevention [1]. Vitamin D synthesis is mediated via
mitochondrial cytochrome P450 family hydroxylase enzymatic reactions: anabolic and
catabolic hydroxylases (CYP27A1, CYP27B1, and CYP24A1). The importance of vitamin
D mitochondrial enzymes in some cancers have been reported, however their role in NMSC
requires further evaluation. CYP24A1 protein expression in lung adenocarcinoma patients
was reported up to 50 folds greater compared to healthy lung and significantly higher in
poorly differentiated cancers types. The survival was proportional to the level of CYP24A1
expression (42% survival with high CYP24A1 expression versus 81% survival with low
level CYP24A1). The overexpression of CYP24A1 in lung cancer was concluded to have

an association with poor survival in lung adenocarcinoma patients. Since endogenous
vitamin D degradation is tightly controlled by CYP24A1, the abrogation of vitamin D
antiproliferative effects in lung cancers may be due to CYP24A1 overexpression [2]. It is
clear that low circulatory vitamin D levels are linked to decreased VDR activity in
endometrial and breast cancer, and deletion of VDR results in decreased tumor suppressor
genes (H19, HOTTIP, Nespas, Kcnq1ot1, lincRNA-p21, Foxn2-as, Gtl2-as, and H19-as) and
increased oncogenes (mHOTAIR, Malat1, and SRA). In fact, VDR suppresses oncogenes,
induces tumor suppressor genes, inhibits cell proliferation and migration of malignant cells,
and prevents metastasis and angiogenesis in cancer [3]. Interestingly, VDR single nucleotide
polymorphisms have been linked to actinic keratosis (AK) development and poor survival of
melanoma patients [4]. These reports indicated that polymorphisms in VDR resulted in less
transcriptionally active VDR, with less efficient interactions with transcriptional factors and
decreased growth inhibition by vitamin D [5]. It is suggested that VDR and vitamin D
metabolic enzymes interact with tumor regulatory proteins in malignant cells, influencing
tumor formation, growth and preventing angiogenic spread [6]. Hence, tumor promotion
and progression is connected to VDR and its metabolic enzymes. Vitamin D hydroxylases
may play an important role in tumorigenesis. Their functions extend beyond vitamin D
synthesis and degradation. Reduced enzymatic activity of CYP27B1 is noted in aggressive
types of melanomas [7]. CYP27A1 modulates VDR activation and plays a pivotal role in
carcinogenesis. The preventative effects of high endogenous vitamin D levels in the
development of neoplastic growth and its aggressiveness have been demonstrated.
Metastatic types of NMSC are often associated with squamous cell carcinoma (SCC) lesions.
However the most common type of NMSC is basal cell carcinoma (BCC) and AK known as
a common precursor of SCC, which has the potential for metastatic spread [8]. BCC and SCC
have important morphological differences and different metastatic potential. Whilst
metastatic BCC is a less common condition, both BCC and SCC are malignant. Therefore, it
is crucial to establish the status of intratumoral vitamin D enzymes and receptor.
Herein, the intratumoral expression of mitochondrial vitamin D enzymes and VDR in
BCC, SCC, SCC in situ (SCCIS), AK and normal skin were determined by standard
immunohistochemistry (IHC) tissue staining using biotinylated universal antibody
streptavidin–biotin (LSAB+) System–HRP (K4063) and diaminobenzidine (Dako Botany,
Australia). The primary unconjugated polyclonal antibodies (Santa Cruz Biotechnology,
Santa Cruz, USA) were used at the optimized dilutions (1:1000): goat anti-human
CYP27A1, rabbit anti-human CYP27B1, rabbit anti-human CYP24A1, and rabbit

anti-human VDR. The secondary antibodies (Dako) were also used at their optimized
dilutions (1:500): anti-mouse HRP, polyclonal rabbit anti-goat Ig, and polyclonal goat
anti-rabbit Ig. All antibodies as supplied by the respective companies were characterized
and validated for specificity by western blotting [9]. Tissue sections were received from the
Department of Dermatology, St Vincent’s Hospital (Melbourne, Australia) or purchased
from Resolving Images Pty Ltd (Melbourne, Australia). In total, 20 BCCs, 15 AKs, 12
SCCISs, 8 SCCs and 5 normal skin tissues were stained from patients aged 41–93 years
following informed consent and human ethics was obtained from the Department of
Dermatology, St Vincent’s Hospital and Victoria University, Australia. Detections of
vitamin D metabolic enzymes (CYP27A, CYP27B1 and CYP24A1) and its receptors (VDR)
in human NSK, AK, BCC, SCC and SCCIS are shown in Figs. 1 and 2. A summary of tissues
stained with respective antibodies and expression levels and number of tissues positive are
shown in Table 1. VDR showed uniform moderate to high expression in most tissues
particularly in epidermal keratinocytes and to a lesser degree in keratinocytes of basal layers
in AK, SCC and SCCIS. The expression of VDR in BCC is present in keratinocytes of all
epidermal layers. In addition, VDR was shown to have a statistically significant association
with CYP24A1 in all tumors, but not with NSK (P<0.001). CYP27A1 detection was very
prominent in NSK, AK and SCCIS, with lower expression in some SCC and BCC.
CYP27A1 expression was strongly associated (P<0.05) with CYP24A1 expression in BCC
and SCCIS and almost reached significant association with CYP24A1 expression in SCC
(P=0.052), and no association in NSK (P>0.05). CYP27B1 was expressed in NSK and most
SCCIS with lower expression in most precancerous (AK) tissues and cancerous tissues (BCC
and SCC). Inverse significant association was noted between CYP27B1 and CYP24A1
expression in all NMSC lesions, but not in NSK. The distribution of CYP24A1 expression
was very different in all tumors and NSK. In AK, BCC, SCC and SCCIS there was intense
CYP24A1 expression, whereas in most NSK tissues the expression of CYP24A1 was
decreased. Specificity of the antibodies used on normal keratinocytes and malignant
squamous keratinocytes (SCC-4 cells), and the effects of calcidiol and calcitriol on the
expression of CYP27A1, CYP27B1, CYP24A1, and VDR on these cell lines were confirmed
and assessed by western blotting (data not shown). The expression and correlation analysis of
vitamin D metabolic proteins and VDR in tumor sections and normal skin was determined by
IBM Statistical Package for the Social Sciences (SPSS) software using Multivariable
Cross-tabulation Chi-Square test. Correlations were considered statistically significant with
P < 0.05.

In summary, vitamin D metabolic enzymes and VDR expression in human NMSC
were found to have statistically significant correlations amongst CYP27A1, CYP24A1 and
VDR, but not CYP27B1. We present data that shows CYP27B1 to be diminished in
NMSC, compared to normal skin, whilst CYP24A1 was elevated in most tumors, but not in
normal skin. These findings are consistent with previous studies in ovarian carcinomas
[10], where CYP24A1 overexpression in malignant cells was noted, whilst CYP27B1
expression was highly reduced.
We report crucial differences in the expression of CYP27B1 and CYP24A1 in normal
and neoplastic tissues. These findings contribute to a better understanding of vitamin D
metabolism in cutaneous carcinogenesis and could be used as an aid in the management of
NMSC, particularly for further prognosis of disease recurrence.
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Figure Legends

Figure 1. Immunoperoxidase staining of skin tissues (NSK, AK, BCC, BCC, SCC,
SCCIS) for the expressions of VDR, CYP27A1, CYP27B1 and CYP24A1

Disruptions

of the basal membrane by neoplastic keratinocytes are indicated with ‘diamond-ended’
arrows. Immune cell infiltration is shown with ‘circled-ended’ arrows. The positively stained
neoplastic, premalignant and normal keratinocytes are shown with solid black arrows and are
indicative of the tissue staining intensity. Poorly differentiated keratinocytes are shown with
black dashed arrows, where applicable. Scale bar: 20 µm. E, epidermal layer; D, dermal
layer.

Figure 2. High magnification immunoperoxidase staining of skin tissues (AK, BCC,
SCC) for the expressions of CYP27B1 and CYP24A1 At high magnification (x 400) in
hyperproliferative and poorly differentiated keratinocytes minimal expression of CYP27B1

is noticeable. Elevated CYP24A1 expression is noted in AK and most BCC and SCC tissues.
Scale bar: 50 µm.

Table 1. The expressions of VDR, CYP27A, CYP27B1 and CYP24A1 in NMSC tissues
and normal skin

Table 1. The expression of VDR, CYP27A, CYP27B1 and CYP24A1 in NMSC tissues and
normal skin
Protein

Low levels of

Moderate levels

High levels of

expression

of expression

expression

(0-5%)

(5-10%)

(> 10%)

Normal skin
Vitamin D CYP27A1 (CYP27A1)

0

0

5

CYP27B1 (CYP27B1)

1

1

3

Vitamin D3 24-hydroxylase

3

1

1

0

0

5

Vitamin D CYP27A1 (CYP27A1)

0

2

13

CYP27B1 (CYP27B1)

9

2

4

Vitamin D3 24-hydroxylase

0

0

15

1

2

12

Vitamin D CYP27A1 (CYP27A1)

5

6

10

CYP27B1

12

5

4

1

3

17

1

2

18

Vitamin D CYP27A1 (CYP27A1)

2

4

2

CYP27B1 (CYP27B1)

4

4

0

Vitamin D3 24-hydroxylase

1

2

5

1

4

3

Vitamin D CYP27A1 (CYP27A1)

2

2

8

CYP27B1 (CYP27B1)

3

9

0

Vitamin D3 24-hydroxylase

1

2

9

2

2

8

(CYP24A1)
VDR
Actinic keratosis neoplastic lesions

(CYP24A1)
VDR
Basal cell carcinoma

(CYP27B1)
Vitamin D3 24-hydroxylase
(CYP24A1)
VDR
Squamous cell carcinoma

(CYP24A1)
VDR
Squamous cell carcinoma in situ

(CYP24A1)
VDR

Supplementary Table
The association of CYP24A1 with CYP27A1, CYP27B1 and VDR expression in NMSC; The
multivariable Cross-tabulation Chi-Square analysis

CYP24A1
NSK
Pearson
-0.802
Correlatio
n R values
p values
0.096

CYP27A1
AK BCC SCC SCCIS NSK
0.708

0.691

0.750

0.875

0.563

0.03

0.001

0.052

0.0002 0.324

CYP27B1
AK BCC
SCC SCCIS NSK
-0.183 -0.383

0.05

0.044

AK

-0.707

-0.93

0.698

-0.808
.

0.048

0.002

0.101

0.001

VDR
BCC

SCC SCCIS

0.991

0.832

0.955

0.0001

0.001

0.001

